Literature DB >> 8564969

Selective damage to carcinoma mitochondria by the rhodacyanine MKT-077.

J S Modica-Napolitano1, K Koya, E Weisberg, B T Brunelli, Y Li, L B Chen.   

Abstract

We investigated the mitochondrial toxicity of the lipophilic cation, MKT-077, and the role of mitochondria in selective malignant cell killing by this compound by examining the effect of MKT-077 on mitochondrial structure and function in treated cells and in isolated organelles. Results of this study demonstrate changes in mitochondrial ultrastructure that are induced by MKT-077 treatment in carcinoma cells but not in similarly treated normal epithelial cells. In addition, MKT-077 was found to inhibit respiratory activity in isolated intact mitochondria and electron transport activity in freeze-thawed mitochondrial membrane fragments in a dose-dependent manner. The concentration of MKT-077 necessary to obtain half-maximal inhibition of ADP-stimulated respiration was approximately 4-fold greater in mitochondria isolated from cells of the normal epithelial cell line, CV-1 (15 micrograms MKT-077/mg protein), as compared to the human colon carcinoma cell line, CX-1 (4 micrograms MKT-077/mg protein). Further, the data show a selective loss of mitochondrial DNA in CX-1 and CRL1420 cells (carcinoma) but not CV-1 cells (normal epithelial) treated with 3 microgram/ml MKT-077 for up to 3 days. Under the same conditions, nuclear DNA was unaffected in all three cell lines. The sensitivity of the cell lines tested to mitochondrial damage by MKT-077 correlates well with their sensitivity to cytotoxicity by MKT-077. These results demonstrate selective mitochondrial damage by MKT-077 at the cellular, biochemical, and molecular levels and suggest that selective effects on mitochondrial structure and function may provide a basis for the selective malignant cell killing exhibited by this compound.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8564969

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

Review 1.  Mitochondria: pharmacological manipulation of cell death.

Authors:  Lisa Bouchier-Hayes; Lydia Lartigue; Donald D Newmeyer
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 2.  Mitochondria: a target for cancer therapy.

Authors:  Jeffrey S Armstrong
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 3.  Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases.

Authors:  Amanda K Davis; William B Pratt; Andrew P Lieberman; Yoichi Osawa
Journal:  Cell Mol Life Sci       Date:  2019-09-24       Impact factor: 9.261

Review 4.  Small mitochondria-targeting molecules as anti-cancer agents.

Authors:  Feng Wang; Marcia A Ogasawara; Peng Huang
Journal:  Mol Aspects Med       Date:  2009-12-06

5.  Peptide deformylase inhibitors as potent antimycobacterial agents.

Authors:  Jeanette W P Teo; Pamela Thayalan; David Beer; Amelia S L Yap; Mahesh Nanjundappa; Xinyi Ngew; Jeyaraj Duraiswamy; Sarah Liung; Veronique Dartois; Mark Schreiber; Samiul Hasan; Michael Cynamon; Neil S Ryder; Xia Yang; Beat Weidmann; Kathryn Bracken; Thomas Dick; Kakoli Mukherjee
Journal:  Antimicrob Agents Chemother       Date:  2006-09-11       Impact factor: 5.191

Review 6.  Mitochondrial contributions to cancer cell physiology: redox balance, cell cycle, and drug resistance.

Authors:  A Dorward; S Sweet; R Moorehead; G Singh
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

7.  Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics.

Authors:  Mona D Lee; Yuhong She; Michael J Soskis; Christopher P Borella; Jeffrey R Gardner; Paula A Hayes; Benzon M Dy; Mark L Heaney; Mark R Philips; William G Bornmann; Francis M Sirotnak; David A Scheinberg
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

8.  Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels.

Authors:  Yoshinari Miyata; Xiaokai Li; Hsiu-Fang Lee; Umesh K Jinwal; Sharan R Srinivasan; Sandlin P Seguin; Zapporah T Young; Jeffrey L Brodsky; Chad A Dickey; Duxin Sun; Jason E Gestwicki
Journal:  ACS Chem Neurosci       Date:  2013-03-20       Impact factor: 4.418

9.  The isatin-Schiff base copper(II) complex Cu(isaepy)2 acts as delocalized lipophilic cation, yields widespread mitochondrial oxidative damage and induces AMP-activated protein kinase-dependent apoptosis.

Authors:  Giuseppe Filomeni; Sara Piccirillo; Ilaria Graziani; Simone Cardaci; Ana M Da Costa Ferreira; Giuseppe Rotilio; Maria R Ciriolo
Journal:  Carcinogenesis       Date:  2009-04-30       Impact factor: 4.944

Review 10.  Pharmacological targeting of the Hsp70 chaperone.

Authors:  Srikanth Patury; Yoshinari Miyata; Jason E Gestwicki
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.